STOCK TITAN

CervoMed CEO John J. Alam buys 76,319 and 23,681 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

CEO and President John J. Alam purchased 23,681 shares at $1.5140 per share and 76,319 shares at $1.5300 per share in open-market transactions on November 18, 2026. The purchases were not reported under a Rule 10b5-1 plan. Ownership notes also list 1,471,578 shares held jointly by Alam and his spouse, Dr. Sylvie Gregoire, PharmD, a member of CervoMed’s Board of Directors; 112,500 shares held by Alam’s Roth IRA; and 12,500 shares held by Gregoire’s Roth IRA.

Insider ALAM JOHN J
Role CEO & President
Bought 100,000 shs ($153K)
Increase in Position 6.7%
Type Security Shares Price Value
Purchase Common Stock F1, F2 23,681 $1.514 $36K
Purchase Common Stock F1, F2 76,319 $1.53 $117K
Holding Common Stock F3 -- -- --
Holdings After Transaction: Common Stock — 1,584,078 shares (Direct); Common Stock — 12,500 shares (Indirect, Spouse's IRA)
Holdings Before and After: Common Stock, 1,484,078 to 1,584,078 shares (Direct)
Footnotes (3)
  1. F1. Shares purchased in open-market transactions.
  2. F2. Includes (i) 1,471,578 shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors, and (ii) 112,500 shares held by the John J. Alam Roth IRA.
  3. F3. Shares held by the Sylvie Gregoire Roth IRA.
Shares purchased 23,681 shares Open-market transaction on November 18, 2026, at $1.5140 per share.
Price per share $1.5140 per share Open-market purchase of 23,681 shares on November 18, 2026.
Shares purchased 76,319 shares Open-market transaction on November 18, 2026, at $1.5300 per share.
Price per share $1.5300 per share Open-market purchase of 76,319 shares on November 18, 2026.
Jointly held shares 1,471,578 shares Held jointly by John J. Alam and Dr. Sylvie Gregoire, PharmD, a member of CervoMed’s Board of Directors.
John J. Alam Roth IRA shares 112,500 shares Shares held by John J. Alam’s Roth IRA.
Sylvie Gregoire Roth IRA shares 12,500 shares Shares held by Dr. Sylvie Gregoire’s Roth IRA.
open-market transactions financial
"Shares purchased in open-market transactions."
Open-market transactions are purchases or sales of a company’s securities that take place on public exchanges rather than through private agreements. They matter to investors because these trades change the number of shares available, can move the stock price, and often signal management’s view of the company’s value—like a store restocking or clearing shelves, altering supply and the price shoppers see.
Roth IRA financial
"Shares held by the Sylvie Gregoire Roth IRA."
A Roth IRA is a retirement savings account you fund with money that’s already been taxed, and withdrawals taken in retirement under the account rules are tax-free. It matters to investors because it shifts the tax bill to today instead of retirement, potentially increasing after-tax income later—think of it like paying for a lifetime subscription now so you can use it without extra charges in the future—helpful for long-term tax planning and flexibility.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CRVO shares did CEO and President John J. Alam buy?

John J. Alam bought 23,681 shares at $1.5140 per share and 76,319 shares at $1.5300 per share on November 18, 2026. The purchases were open-market transactions and were not reported under a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ALAM JOHN J

(Last)(First)(Middle)
20 PARK PLAZA, SUITE 424

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
CEO & President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/18/2026P23,681(1)A$1.5141,507,759(2)D
Common Stock11/18/2026P76,319(1)A$1.531,584,078(2)D
Common Stock12,500(3)ISpouse's IRA(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares purchased in open-market transactions.
2. Includes (i) 1,471,578 shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors, and (ii) 112,500 shares held by the John J. Alam Roth IRA.
3. Shares held by the Sylvie Gregoire Roth IRA.
/s/ John Alam11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading